Chembio Diagnostics (NASDAQ:CEMI) released its earnings results on Thursday. The company reported ($0.22) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.05), Fidelity Earnings reports. The firm had revenue of $9.72 million during the quarter. Chembio Diagnostics had a negative net margin of 32.95% and a negative return on equity of 39.62%.
Shares of CEMI traded down $0.47 on Friday, reaching $4.54. The stock had a trading volume of 153,300 shares, compared to its average volume of 50,394. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.98 and a current ratio of 3.38. Chembio Diagnostics has a 12-month low of $4.39 and a 12-month high of $7.90. The firm has a market capitalization of $94.85 million, a price-to-earnings ratio of -8.25 and a beta of 1.68. The company has a 50-day simple moving average of $5.77 and a 200-day simple moving average of $6.15.
A number of research analysts have recently commented on the company. Canaccord Genuity restated a “buy” rating and issued a $10.00 target price on shares of Chembio Diagnostics in a research note on Monday, July 22nd. ValuEngine cut Chembio Diagnostics from a “buy” rating to a “hold” rating in a research note on Monday, November 4th.
About Chembio Diagnostics
Chembio Diagnostics, Inc, together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi.
Featured Article: What is a front-end load?
Receive News & Ratings for Chembio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.